Pfizer announced Tuesday that they have begun testing their COVID-19 vaccine on children under 12 years old, and for some trials as young as 6 months.
The new trials include over four thousand children who will receive doses at 90 testing locations across the U.S. as well as in Finland, Poland and Spain. Pfizer had already completed a phase of testing that included almost 150 children, all under 12, the last group to not have emergency approval from the federal government.
In March, Moderna began testing its vaccine in younger children as well. That trial included 6,750 healthy children in the United States and Canada. Results of these Moderna trials are not expected to be released until the end of the summer, and because of this, the authorization by the F.D.A. will take longer.
Coronavirus vaccines may be widely available by the fall for U.S. children as young as 6 months, drugmakers say. Some schools may move to mandate the vaccines for children to be able to return to classes without masks.
Former Pfizer VP, Dr Michael Yeadon has been making his rounds on various outlets, warning about the reported surge in adverse events from the experimental MRNA vaccines. In a recent appearance, Dr Yeadon spoke about these adverse events, saying that ‘it makes no sense’ to vaccinate children with a vaccine that is statistically ’50 times more likely’ to kill the child than the virus itself.
This comes at a time when the advisory panel of the Centers for Disease Control (CDC) plans on holding an emergency meeting on June 18 to discuss reports of heart inflammation after doses of COVID-19 vaccine.
The meeting comes as the CDC looks into cases of myocarditis, inflammation of the heart muscles, in young people and adolescents who received the shot.
Immunologists like Dr Byram Bridle have also recently spoken out about newly obtained data showing the accumulation of spike proteins in vital organs of the body, which experts call the likely culprit of the serious blood clotting and other adverse events the CDC’s VAERS system has been reporting.
According to all available data, the virus has an infection fatality rate that is either equivalent to, or far less than influenza for most age groups.
The Infection Fatality Rate (IFR) is the total number of deaths divided by the total number of people that carry the infection, regardless of them having clinical symptoms or not. The IFR is the chance of death once you have the virus.
For children, the average IFR is around .001.
An article on seven U.S. teen boys in several states published by the AP in Pediatrics, is among the latest of reports regarding heart inflammation in children discovered after COVID-19 vaccination.
VAERS, the CDC’s primary mechanism in the U.S. for reporting adverse vaccine reactions, historically only reports 1% of the total actual adverse events according to a Harvard study.
This latest number of reported deaths among all age groups following COVID-19 vaccines passed the 5,000 mark, up 759 from the prior week, according to data released recently.
Some experts say, if VAERS only reports approximately 1% of the total adverse events from vaccines, the hundreds of thousands already reported to VAERS by healthcare professionals could possibly be really in the millions.
The newest data show that between Dec. 14, 2020 and May 28, a total of 294,801 total adverse events were reported to VAERS, including 5,165 deaths. There were 25,359 serious injuries reported, up 3,822 compared with the prior week.
A recent report by the New York Times, showed that people who have been naturally infected with coronavirus have natural immunity that will likely last for years, and maybe forever. Many experts have suggested that natural immunity is a much better option than immunity from the new vaccines, especially for children.
“After infection, most people who have recovered still have enough immune cells to fend off the virus and prevent illness, the new data show. A slow rate of decline in the short term suggests, happily, that these cells may persist in the body for a very, very long time to come,” the New York Times reports.
For most viruses it is generally the scientific consensus that natural infection provides a better and more robust immunity than vaccines are able to.
For example, a recent SIREN study conducted in the UK at the Public Health England (PHE) involving over 20,000 healthcare professionals has discovered that immunity derived by natural COVID-19 infection is stronger and more effective at warding off the novel coronavirus than the vaccine developed by Oxford-AstraZeneca.
A U.S.-based vaccine company, MERK, also announced on Jan. 25th that they will stop developing vaccines for the coronavirus since natural infections are better than vaccines in producing results leading to herd immunity.